Literature DB >> 28430872

Optimal screening schedules for disease progression with application to diabetic retinopathy.

Ionut Bebu1, John M Lachin1.   

Abstract

Clinical management of chronic diseases requires periodic evaluations. Subjects transition between various levels of severity of a disease over time, one of which may trigger an intervention that requires treatment. For example, in diabetic retinopathy, patients with type 1 diabetes are evaluated yearly for either the onset of proliferative diabetic retinopathy (PDR) or clinically significant macular edema (CSME) that would require immediate treatment to preserve vision. Herein, we investigate methods for the selection of personalized cost-effective screening schedules and compare them with a fixed visit schedule (e.g., annually) in terms of both cost and performance. The approach is illustrated using the progression of retinopathy in the DCCT/EDIC study. The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Diabetic retinopathy; Markov models; Optimal screening schedule; Undetected time

Mesh:

Year:  2018        PMID: 28430872      PMCID: PMC6075595          DOI: 10.1093/biostatistics/kxx009

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  8 in total

1.  Flexible nonhomogeneous markov models for panel observed data.

Authors:  Andrew C Titman
Journal:  Biometrics       Date:  2011-02-09       Impact factor: 2.571

2.  Multi-state models and diabetic retinopathy.

Authors:  G Marshall; R H Jones
Journal:  Stat Med       Date:  1995-09-30       Impact factor: 2.373

3.  Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.

Authors:  David M Nathan; Ionut Bebu; Dean Hainsworth; Ronald Klein; William Tamborlane; Gayle Lorenzi; Rose Gubitosi-Klug; John M Lachin
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

4.  Intensive diabetes therapy and ocular surgery in type 1 diabetes.

Authors:  Lloyd Paul Aiello; Wanjie Sun; Arup Das; Sapna Gangaputra; Szilard Kiss; Ronald Klein; Patricia A Cleary; John M Lachin; David M Nathan
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

5.  Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

6.  Cost-effectiveness of strategies for detecting diabetic retinopathy.

Authors:  E J Dasbach; D G Fryback; P A Newcomb; R Klein; B E Klein
Journal:  Med Care       Date:  1991-01       Impact factor: 2.983

7.  Glycemic exposure and blood pressure influencing progression and remission of diabetic retinopathy: a longitudinal cohort study in GoDARTS.

Authors:  Yiyuan Liu; Minghui Wang; Andrew D Morris; Alex S F Doney; Graham P Leese; Ewan R Pearson; Colin N A Palmer
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

8.  Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.

Authors:  John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

  8 in total
  3 in total

1.  Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.

Authors:  David M Nathan; Ionut Bebu; Dean Hainsworth; Ronald Klein; William Tamborlane; Gayle Lorenzi; Rose Gubitosi-Klug; John M Lachin
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

2.  Early Screening for Diabetic Retinopathy in Newly Diagnosed Type 2 Diabetes and Its Effectiveness in Terms of Morbidity and Clinical Treatment: A Nationwide Population-Based Cohort.

Authors:  Yu-Chien Chung; Ting Xu; Tao-Hsin Tung; Mingchih Chen; Pei-En Chen
Journal:  Front Public Health       Date:  2022-04-26

3.  Shared decision making of burdensome surveillance tests using personalized schedules and their burden and benefit.

Authors:  Anirudh Tomer; Daan Nieboer; Monique J Roobol; Ewout W Steyerberg; Dimitris Rizopoulos
Journal:  Stat Med       Date:  2022-02-10       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.